Taysha Gene Therapies Inc (NASDAQ: TSHA) kicked off on Tuesday, down -8.87% from the previous trading day, before settling in for the closing price of $1.24. Over the past 52 weeks, TSHA has traded in a range of $1.10-$4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 94.30%. While this was happening, its average annual earnings per share was recorded -1.42%. With a float of $165.01 million, this company’s outstanding shares have now reached $204.94 million.
Let’s determine the extent of company efficiency that accounts for 73 employees. In terms of profitability, gross margin is 100.0%, operating margin of -1097.55%, and the pretax margin is -1071.62%.
Taysha Gene Therapies Inc (TSHA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Taysha Gene Therapies Inc is 19.51%, while institutional ownership is 77.26%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -1.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.46% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Take a look at Taysha Gene Therapies Inc’s (TSHA) current performance indicators. Last quarter, stock had a quick ratio of 5.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Looking closely at Taysha Gene Therapies Inc (NASDAQ: TSHA), its last 5-days average volume was 2.03 million, which is a drop from its year-to-date volume of 2.17 million. As of the previous 9 days, the stock’s Stochastic %D was 8.80%. Additionally, its Average True Range was 0.16.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 1.36%, which indicates a significant decrease from 3.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 150.07% in the past 14 days, which was higher than the 115.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6147, while its 200-day Moving Average is $1.9775. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $1.2400. Second resistance stands at $1.3500. The third major resistance level sits at $1.4100. If the price goes on to break the first support level at $1.0700, it is likely to go to the next support level at $1.0100. Should the price break the second support level, the third support level stands at $0.9000.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
The company with the Market Capitalisation of 231.65 million has total of 205,002K Shares Outstanding. Its annual sales at the moment are 8,330 K in contrast with the sum of -89,300 K annual income. Company’s last quarter sales were recorded 2,020 K and last quarter income was -18,780 K.
